Compare United States Copper Index Fund (CPER) vs Mesoblast Limited (MESO) Price & Performance

United States Copper Index FundTrade

Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

United States Copper Index Fund vs Mesoblast Limited — how do they compare? United States Copper Index Fund trades at $38.39, while Mesoblast Limited trades at $17.69 (market cap $2.12B). The key difference: United States Copper Index Fund is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.

	CPER	MESO
Sector	Commodities - Metals/Agriculture	Technology
52-Week High	$40.60	$20.96
52-Week Low	$27.21	$10.96
Market Cap	—	$2.12B
Enterprise Value	—	$2.13B

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

CPER

Investors choose between copper miners ETF and copper futures fund for EV-driven demand exposure.24/7 Wall Street · 3 days agoBullish View details →

MESO

Mesoblast completes treatment of 300 patients in Phase 3 trial for chronic low back pain therapy.GlobeNewsWire · 1 day agoBullish Mesoblast advances to commercial stage with FDA-approved Ryoncil and strong early revenue growth.Seeking Alpha · 4 days agoBullish View details →

About United States Copper Index Fund

CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.